OATP2B1 Deficiency Ameliorates Irinotecan‐Induced Gastrointestinal Toxicity
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Hanieh Taheri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutics and Pharmacology, College of Pharmacy, the Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Camptothecin, Organic Anion Transporters, Topoisomerase I Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Irinotecan (CPT‐11) is a prodrug of the topoisomerase I inhibitor SN‐38 used in the treatment of metastatic carcinomas of the colon or rectum. The clinical utility of this drug is hindered by debilitating side effects, most notably, severe gastrointestinal toxicity, which affects up to 40% of patients. Although the accumulation of SN‐38 in intestinal enterocytes, following biliary secretion and microbial metabolism of its glucuronide metabolite, is believed to be a critical preceding event to CPT‐11‐induced toxicity, the transport mechanism involved in this process remains incompletely understood. Here, we tested the hypothesis that the organic anion transporting polypeptide OATP2B1 is an intestinal uptake transporter of SN‐38 and a critical determinant of CPT‐11‐induced toxicity. Mice with Oatp2b1 deficiency experienced milder diarrhea and reduced changes in their intestine length, a known injury marker, compared to wild‐type mice when subjected to CPT‐11 treatment. These observations were confirmed by a histological examination indicating that damage to intestinal enterocytes was more severe in wild‐type mice. The phenotypic alterations in Oatp2b1‐deficient mice occurred without substantial changes in measures of systemic exposure to the parent drug, SN‐38, or its glucuronide conjugate. Collectively, our study indicates that plasma concentrations of SN‐38 are a poor predictive biomarker of CPT‐11‐induced gastrointestinal toxicity and provides an incentive for the future development of intervention strategies aimed at increasing the tolerance to this clinically important drug with the use of OATP2B1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmaceutics and Pharmacology, College of Pharmacy, the Ohio State University, Columbus, Ohio, USA.
- Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, GD, the Netherlands.
- Department of Veterinary Biosciences, College of Veterinary Medicine, the Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Ron H J Mathijssen, Kevin M Huang, Alex Sparreboom, Shuiying Hu
Förderung
- NCI NIH HHS
Zitieren
APA
Taheri, H., de Bruijn, P., Li, Y., Kleinert, N. R., Corps, K. N., Mathijssen, R. H. J., Huang, K. M., Sparreboom, A., & Hu, S. (2026). OATP2B1 Deficiency Ameliorates Irinotecan‐Induced Gastrointestinal Toxicity. Clinical and Translational Science. https://doi.org/10.1111/cts.70452
Vancouver
Taheri H, de Bruijn P, Li Y, Kleinert NR, Corps KN, Mathijssen RHJ, et al. OATP2B1 Deficiency Ameliorates Irinotecan‐Induced Gastrointestinal Toxicity. Clinical and Translational Science. 2026. doi:10.1111/cts.70452
BibTeX
@article{Taheri2026,
author = {Taheri, Hanieh and de Bruijn, Peter and Li, Yang and Kleinert, Nicholas R and Corps, Kara N and Mathijssen, Ron H J and Huang, Kevin M and Sparreboom, Alex and Hu, Shuiying},
title = {OATP2B1 Deficiency Ameliorates Irinotecan‐Induced Gastrointestinal Toxicity},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70452}
}
EUVIMED